Innovent Biologics

HKG:1801 · KYG4818G1010

BiotechnologyLarge

360

Value40

Profit price3

EV / EBIT5

Price / Owner Earnings1

Cash yield31

Owner Earnings Yield61

Dividend Yield1

Sales & asset price31

Price/Sales16

EV / Gross Profit56

Price/Book20

Quality67

Returns on capital65

Return on Capital66

Cash Return on Capital67

Return on Equity63

Profit margins53

EBIT Margin51

Gross Profitability54

Cash backing74

Cash Conversion100

Accruals61

Owner Earnings Margin61

Growth49

Sales growth89

Profit growth52

Profit Growth83

Long-Term EPS Growth19

Owner Earnings Growth54

Reinvestment84

Price momentum58

Safety62

Debt load69

Debt serviceability60

Refinancing20

Debt Payback100

Liquidity52

Sentiment51

Analyst ratings81

Expectations trend72

Opinion Changes67

Price Target Upside77

Market mood97

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Innovent Biologics clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryChina

IndustryBiotechnology

SizeLarge

TypePublic Company

ExchangeSEHK

Founded2011

Employees315

Websiteinnoventbio.com

ISINKYG4818G1010

Last UpdateApr 2, 2026

Indices

Hang Seng (Hong Kong)

Themes

ImmunologyOphthalmologyCardiovascularOncologyBiopharmaBiotechnologyManufacturing

Description

Innovent Biologics, Inc. is a biopharmaceutical company committed to developing and commercializing high-quality innovative therapeutics that are affordable to ordinary people. The company has built a fully integrated multi-functional biopharmaceutic…

Analysis

Quality compounder

Innovent Biologics, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is expensive. You pay 104.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 10/20 on our value-creation score: creating some value.

What to watch: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Feb 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Innovent Biologics with its peers

Samsung Epis

KSC:0126Z0

CountrySouth Korea

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Celltrion

KSC:068270

CountrySouth Korea

IndustryBiotechnology

SizeLarge

Full Stock Analysis →

Mesoblast

ASX:MSB

CountryAustralia

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Jyong Biotech

NMQ:MENS

—

CountryTaiwan

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

GC Biopharma

KSC:006280

CountrySouth Korea

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Clinuvel Pharmaceuticals

ASX:CUV

CountryAustralia

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →